This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

LipiGesic M Is The Only Recommended First-line Therapy For Acute Migraine That Has No Evidence Of Rebound Headache

In most cases, the only way for adults or children to stop the rebound effect is to stop taking the offending medication. This, however, should be done under a physician's care since it usually results in a severe withdrawal headache that may be accompanied by nausea, vomiting, restlessness, and disturbed sleep.

About LipiGesic M:Results of a double-blind, placebo-controlled clinical trial for LipiGesic M show LipiGesic M is a highly effective treatment for acute migraine. The study was published in the July 2011 issue of the top-tier medical journal, Headache: The Journal of Head and Face Pain. LipiGesic M has national distribution and is available nationwide in Walgreens and CVS/pharmacy stores nationwide. In addition to LipiGesic M, the Company also has plans to launch LipiGesic H, tension headache remedy, as well as LipiGesic PM, a remedy for insomnia and other sleep disorders. www.lipigesic.com

As of August 01, 2013, the Company currently had around 43 million common shares issued and outstanding.

Forward-Looking Statements:This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:PuraMed BioScience, Inc. Russell Mitchell, Chairman and CEO715-359-6373 rmitchell@PuramedBioScience.com www.PuramedBioScience.com

SOURCE PuraMed BioScience, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs